Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Watson buys Belgium-based Uteron for $150M up front plus $155M in milestones, adding hormonal IUD, novel OC, and an IVF diagnostic to its women's health…
Coincident with the Uteron close, Watson announced its corporate rebrand to Actavis as it absorbed the prior Actavis Group acquisition.
The acquisition strengthens Watson's originator pipeline within Global Brands and capitalizes on growing women's health franchise after Actavis Switzerland…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Watson acquired Belgium-based Uteron Pharma for $150M cash upfront + up to $155M milestones; expanded Global Brands women's health pipeline (contraception, infertility, IUDs).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Uteron Pharma SA (this deal) | 2013 | $305M | 16 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
← Browse all deals · How we score deals
More: 2013 deals · Watson Pharmaceuticals (Actavis Inc.) deals · Women's Health deals